Gibson W, Green A, Bullard RS, Eaddy AC, and Donald CD. Inhibition of PAX2 expression results in alternate cell death pathways in prostate cancer cells differing in p53 status. Cancer Letters 248: 251-261, 2007
Bullard RS, Gibson W, Bose SK, Belgrave JK, Eaddy AC, Wright CJ, Hazen-Martin DJ, Lage JM, Keane TE, Ganz TA, and Donald CD. Functional Analysis of the Host Defense Peptide Human Beta Defensin-1: New Insight into its Potential Role in Cancer. Molecular Immunology 45(3):839-48, 2008
Bose SK, Gibson W, Bullard RS, Donald CD. PAX2 oncogene negatively regulates the expression of the host defense peptide human beta defensin-1 in prostate cancer. Molecular Immunology 46(6):1140-1148, 2000
Bose SK, Gibson W, Giri S, Nath N, Donald CD. Angiotensin II up-regulates Pax2 oncogene expression and activity in prostate cancer via the angiotensin type I receptor. The Prostate 69(12): 1334-42, 2009
Daye LR, GibsonW, and Williams KP. Development of a high throughput screening assay for inhibitors of hedgehog-heparin interactions. International Journal of High Throughput Screening. 1:69-80, 2010
Thomas ZL, Gibson W, Sexton JZ, Aird, KM, Ingram SM, Aldrich A, Lylerly HK, Devi GR, Williams KP. Targeting GLI1 expression in human inflammatory breast cancer cells enhances apoptosis and attenuates migration.British Journal of Cancer 104: 1575-1586, May 2011
PEER-REVIEWED ABSTRACTS
Comparison of RNA interference Silencing of PAX2 Expression in PC3, Du145, and LNCaP Cell Lines, Presented poster at American Association for Cancer Research 96th national annual meeting, Anaheim, California, April 2005
PAX2 Oncogene Regulates human Beta Defensin-1 Expression and Mediated Cell Death in Prostate Cancer Cell Lines, Presented poster at the American Association for Cancer Research 98th Annual Meeting, Los Angeles, California, April 2007
Dysregulation of the Hedgehog Pathway in Inflammatory Breast Cancer, Presented poster at Duke University Cancer Center Annual Meeting at the Nasher Museum, Durham, NC , March 2008
Hedgehog as a Therapeutic Target for Inflammatory Breast Cancer, Presented oral presentation at the National Organization for the Professional Advancement of Black Chemists & Chemical engineers 2009 Southeast Regional Meeting, Hyattsville, MD, November 2009.
Zainab I Thomas1, Jonathan Z. Sexton1, Willietta Gibson1, Katherine M. Aird2, Amy Aldrich2, Gayathri R. Devi2 and Kevin P. Williams1.Establishment of a high-content assay to assess the affects of gene silencing on inflammatory breast cancer cell motility. Abstract: Cancer Epidemiology Biomarkers & Prevention: October 2010; Volume 19, Issue 10, Supplement 1; Presented at AACR International Conference on the Science of Cancer Health Disparities.